Gordon Brown, DO

Gordon Brown, DO, Summit Health

Articles by Gordon Brown, DO

In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice.

In part five of this NMIBC roundtable, the panelists discuss integrating new therapies such as TAR-200 into clinical practice

Part four of this roundtable series examines the SunRISe-1 trial results for high-risk NMIBC.

The panelists discuss advancements in NMIBC treatment in part three of this roundtable, including pembrolizumab and TAR-200.

Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification.

The first part of this roundtable focuses on recent trial data, the role of TUR quality, and precision medicine for NMIBC.

Gordon Brown, DOUrothelial Carcinoma | December 3, 2024

Dr. Brown shares highlights from the CME program at LUPGA 2024, including new trends in bladder, kidney, and prostate cancer.